PRLD (Prelude Therapeutics) Treasury Stock: $0.00 Mil (As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Treasury Stock?

Prelude Therapeutics PRLD +1.63% 26 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Prelude Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Prelude Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Treasury Stock Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Prelude Therapeutics (PRLD) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Treasury Stock too high?
Prelude Therapeutics' current Treasury Stock is $0.00 Mil. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Treasury Stock compare to DMAC and RCKT?
Prelude Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Prelude Therapeutics and its competitors. Prelude Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price